Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation
about
Side population cells as prototype of chemoresistant, tumor-initiating cellsThe Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.Percutaneous Fine-Needle 5% Ethanol-Cisplatin Intratumoral Injection Combined with Second-Line Chemotherapy Improves On the Standard of Care in Patients with Platinum-Pretreated Stage IV Non-Small Cell Lung CancerCisplatin in 5% Ethanol Eradicates Cisplatin-Resistant Lung Tumor by Killing Lung Cancer Side Population (SP) Cells and Non-SP Cells.The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer.Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activationRole of ABCG2 expression driven by cisplatin in platinum-containing chemotherapy for gastric cancerCancer Stem Cells: A Moving TargetTherapy-induced enrichment of putative lung cancer stem-like cells.Lung cancer stem cells and implications for future therapeutics.Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells.Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms.A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.MicroRNA-320a and microRNA-4496 attenuate Helicobacter pylori cytotoxin-associated gene A (CagA)-induced cancer-initiating potential and chemoresistance by targeting β-catenin and ATP-binding cassette, subfamily G, member 2.Intratumoral injection of cisplatin in various concentrations of ethanol for cisplatin-resistant lung tumors.Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells.ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance.
P2860
Q26823433-730436BA-1209-42A3-B462-263A59210429Q30313205-E7D0D28F-1E74-4CF0-A738-E1294DA72897Q33912220-491EF369-4AF9-4E81-A8C2-14110BE4587EQ34979432-1AC1C37F-2622-477A-BB16-D490F778FAF1Q35095964-BAB5A1C3-FD9A-4491-89CD-0DFE59BBD70AQ35713579-B0DD66A1-94A0-46B0-909A-090D78B84915Q37241606-DDD95CB0-11C4-4C12-8674-3DE174719E15Q38126498-EC6CCB5F-C05B-4360-B96F-613F4C151AF2Q38150766-1277B4DE-1C1F-47C8-A938-6BEA156A762DQ38189297-B2851495-5F9C-4121-8AF5-00BDA154C829Q38618124-6B583CFD-8C9A-446C-945D-E270881666E8Q38749053-9AAA8E59-B66F-4594-983B-A09068FDD8CAQ38986437-B4EA2A7E-B4A9-42AB-A1A6-102FD9C4D832Q39069525-1F554A68-FF54-4A0A-954C-54462CAE8BF9Q40515209-1E0F88A0-DB25-465A-8A83-9D517613A6B2Q46538048-137643E4-EECA-42C2-8472-2D5FD9FE5227Q47118535-37E6A969-C1FA-4696-A91B-C9C0DD00601D
P2860
Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Low molecular weight heparin a ...... ated ABCG2 protein degradation
@ast
Low molecular weight heparin a ...... ated ABCG2 protein degradation
@en
Low molecular weight heparin a ...... ated ABCG2 protein degradation
@nl
type
label
Low molecular weight heparin a ...... ated ABCG2 protein degradation
@ast
Low molecular weight heparin a ...... ated ABCG2 protein degradation
@en
Low molecular weight heparin a ...... ated ABCG2 protein degradation
@nl
prefLabel
Low molecular weight heparin a ...... ated ABCG2 protein degradation
@ast
Low molecular weight heparin a ...... ated ABCG2 protein degradation
@en
Low molecular weight heparin a ...... ated ABCG2 protein degradation
@nl
P2093
P2860
P1433
P1476
Low molecular weight heparin a ...... ated ABCG2 protein degradation
@en
P2093
Douglas M Ruden
Fangying Wang
Fenghua Wang
Jingying Song
P2860
P304
P356
10.1371/JOURNAL.PONE.0041035
P407
P577
2012-01-01T00:00:00Z